5548075
Last Update Posted: 2024-01-19
Recruiting has ended
All Genders accepted | 18 Years + |
20 Estimated Participants | No Expanded Access |
Observational Study | Does not accept healthy volunteers |
Psilocybin in Patients With Fibromyalgia: EEG-measured Brain Biomarkers of Action
The purpose of this study is to assess brain activity under Psilocybin in a cohort of people with fibromyalgia.
This mechanistic (Non-CTIMP) study will utilise a within-subjects design to examine a candidate brain biomarker of increased plasticity under Psilocybin. Up to 25mg of Psilocybin will be administered under standardised conditions on two occasions, separated by four weeks with in-dosing EEG recordings.
The primary end-point will take place 8 weeks from the first dosing session after which patients will be remotely monitored monthly for 6 months.
Eligibility
Relevant conditions:
Fibromyalgia
If you aren't sure if you meet the criteria above speak to your healthcare professional. Criteria may be updated but not reflected here, do not hesitate to contact the trial if you think are close to fitting criteria.
locations
Data sourced from ClinicalTrials.gov